THE CLINICAL DEVELOPMENT OF BIO-SIMILAR PRODUCTS OF INSULIN AND ITS ANALOGUES: MODERN STAGE OF PROGRESSING
- Authors: Philippova A.V.1, Chzhao V.1, Kolbin A.S1,2
-
Affiliations:
- The I.P. Pavlov first St. Peterburgsky state medical university of Minzdrav of Russia
- The St. Peterburgsky state university
- Issue: Vol 23, No 5 (2017)
- Pages: 269-274
- Section: Articles
- URL: https://journals.rcsi.science/0869-2106/article/view/38432
- DOI: https://doi.org/10.18821/0869-2106-2017-23-5-269-274
- ID: 38432
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Anastasiya V. Philippova
The I.P. Pavlov first St. Peterburgsky state medical university of Minzdrav of Russia
Email: a.v.filippova2012@gmail.com
post-graduate student of the chair of clinical pharmacology and evidence medicine the I.P. Pavlov first St. Peterburgsky state medical university of Minzdrav of Russia, 197022, St. Peterburg, Russian Federation 197022, St. Peterburg, Russian Federation
V. Chzhao
The I.P. Pavlov first St. Peterburgsky state medical university of Minzdrav of Russia197022, St. Peterburg, Russian Federation
A. S Kolbin
The I.P. Pavlov first St. Peterburgsky state medical university of Minzdrav of Russia; The St. Peterburgsky state university197022, St. Peterburg, Russian Federation; 199106, St. Petersburg, Russian Federation
References
- Всемирная организация здравоохранения. Российская Федерация: Статистические данные. Available at: http://www.who.int/countries/rus/ru/
- World Health Organization World Health Organization. ВОЗ. Global Diabetes Report. 2015. Available at: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf
- Дедов И.И., Шестакова М.В., Галстян Г.Р., Григорян О.Р., Есаян Р.М., Калашников В.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 7-й выпуск. Сахарный диабет. 2015; 18(Прил. 1): 1-112
- Sheldon B., Russell-Jones D., Wright J. Insulin analogues: an example of applied medical science. Diabetes Obes. Metab. 2009; 11(1): 5-19.
- Company Ely Lilly and Humalog NDA 020563; 1997. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020563a_s003_071697.pdf
- Novo Nordisk Inc Novolog NDA 020986; 2000. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020986 Orig1s061.pdf
- US S.A. Apidra NDA 021629. Approval Letter; 2004. Available at: www.accessdata.fda.gov
- US S.A. Glargin NDA 021081; 2000. Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327015.pdf
- Novo Nordisk Inc Detemir NDA 021878; 2005. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021878s000_LevemirTOC.cfm
- Novo Nordisk Inc Degludec NDA 203314; 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203313and203314Orig1s000TOC.cfm
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency; 2006. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf
- Guideline on Immunogenicity assessment of therapeutic proteins and peptides. European Medicines Agency; 2007. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf
- Heinemann L., Hompesch M. Biosimilar insulins: how similar is similar? J. Diabetes Sci. Technol. 2011; 5(3):741-54.
- Guideline on the investigation of bioequivalence. European Medicines Agency; 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
- Owens D.R., Landgraf W., Schmidt A., Bretzel R.G., Kuhlmann M.K. The emergence of biosimilar insulin preparations - A cause for concern? Diabetes Technol. Ther. 2012; 14(11): 989-96.
- Heinemann L., Khatami H., McKinnon R., Home P. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins. Diabetes Technol. Ther. 2015; 17(7): 1-17.
- Linnebjerg H., Lam E., Zhang X., Seger M.E., Coutant D., Chua L. et al. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obes. Metab. 2017; 19(1): 33-9.
- Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. European Medicines Agency; 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184161.pdf
- Oxford University Press Print Publication; 2010.
- Withdrawal Assessment Report for Insulin Human Rapid Marvel. European Medicines Agency; 2008. Available at: www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067086.pdf
- Jimenez A.G., Brake B. Biosimilars in the European Union - regulatory perspectives. European Medicines Agency. Available at: http://www.ich.org/fileadmin/Public_Web_Site/Training/ASEAN_Q5C_workshop_May_2011/SESSION_IVa_Biosimilars.pdf
- Linnebjerg H., Lam E.C., Zhang X., Seger M.E., Coutant D., Chua L., et al. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obes. Metab. 2017; 19(1): 33-9.
- Hadjiyianni I., Dahl D., Lacaya L.B., Pollom R.K., Chang C.L., Ilag L.L. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus(R) insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obes. Metab. 2016; 18(2): 159-68.
- Pollom R.K. Research letter. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Diabetes Obes. Metab. 2016; 18(4): 425-9.